Form 4 for KNSA Kiniksa Pharmaceuticals International, plc
Accepted 2024-10-17 00:00:00 ET · period of report 2024-10-15 · accession 0001415889-24-025374 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-10-17 | 2024-10-15 | KNSA | Tessari Eben | COO | S - Sale+OE | $26.87 | -17.0K | 110.0K | -13% | -$456.8K |
| D | 2024-10-17 | 2024-10-15 | KNSA | Tessari Eben | COO | M - OptEx | $1.59 | +10.0K | 127.0K | +9% | +$15.9K |
| D | 2024-10-17 | 2024-10-15 | KNSA | Tessari Eben | COO | M - OptEx | $0.00 | -10.0K | 26.0K | -28% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Share | 2024-10-15 | S | D | 17,000 | $26.87 | 109,975 | D | — | — | (F2) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $26.465 and $27.15. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |
| 2 | Common | Class A Ordinary Share | 2024-10-15 | M | A | 10,000 | $1.59 | 126,975 | D | — | — | |
| 3 | Derivative | Share Option | 2024-10-15 | M | D | 10,000 | $0.00 | 26,017 | D | $1.59 · — to 2025-12-15 | 10,000 Class A Ordinary Share | (F3) The option is fully vested and exercisable. |